Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

NCT ID: NCT00303745

Last Updated: 2008-07-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 78 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether irinotecan and capecitabine are more effective than irinotecan alone in treating colorectal cancer.

PURPOSE: This randomized phase II trial is studying irinotecan and capecitabine to see how well they work as second-line therapy compared to irinotecan alone in treating older patients with progressive, metastatic colorectal cancer that cannot be removed by surgery.

Detailed Description

OBJECTIVES:

Primary

• Compare the objective response or stable disease rate in elderly patients with unresectable, progressive, metastatic colorectal cancer treated with irinotecan hydrochloride with vs without capecitabine.

Secondary

• Compare the tolerability of these regimens in these patients.
• Compare the quality of life and ability to maintain self-sufficiency of patients treated with these regimens.
• Compare the progression-free and overall survival of patients treated with these regimens.

OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified according to participating center, WHO performance status (0 or 1 vs 2), number of associated comorbidities (Charlson index 0-2 vs > 2), and age (75-79 vs ≥ 80). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients receive oral capecitabine on days 1-14 and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and then every 12 weeks thereafter.

After completion of study therapy, patients are followed every 12 weeks.

PROJECTED ACCRUAL: A total of 78 patients will be accrued for this study.

Conditions

Colorectal Cancer

Keywords

adenocarcinoma of the colon; recurrent colon cancer; stage IV colon cancer; adenocarcinoma of the rectum; recurrent rectal cancer; stage IV rectal cancer

Study Design

• Allocation Method: RANDOMIZED
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

capecitabine

Intervention Type: DRUG

irinotecan hydrochloride

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic adenocarcinoma of the colon or rectum

• Unresectable disease
• Documented progressive disease during first-line/palliative chemotherapy
• Measurable disease ≥ 1 cm that is outside prior radiation field
• No brain metastases

PATIENT CHARACTERISTICS:

• WHO performance status 0-2
• Life expectancy ≥ 3 months
• No contraindication to chemotherapy
• Creatinine clearance ≥ 40 mL/min
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Alkaline phosphatase ≤ 3 times normal (5 times normal if hepatic involvement)
• Bilirubin ≤ 1.5 times normal
• Transaminases ≤ 5 times normal
• No symptomatic coronary disease or cardiac insufficiency
• No enteropathy or chronic diarrhea
• No unresolved intestinal occlusion or subocclusion
• No history of severe unexpected reaction to a fluoropyrimidine
• No other active malignancy in the past 2 years
• No hypersensitivity to irinotecan hydrochloride or its excipients
• No hypersensitivity to capecitabine or fluorouracil

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior extensive resection
• No concurrent sorivudine or similar analogs (e.g., brivudine)
• No other concurrent anticancer therapy
• Concurrent radiotherapy allowed for nontarget lesions

• Minimum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Federation Francophone de Cancerologie Digestive

OTHER

Sponsor Role: lead

Principal Investigators

Emmanuel Mitry, MD, PhD

Role:

Hopital Ambroise Pare

Thomas Aparicio

Role: STUDY_CHAIR

Hopital Bichat - Claude Bernard

Locations

Centre Hospitalier d'Abbeville

Abbeville, , France

Polyclinique Bordeaux Nord Aquitaine

Boucher, , France

Centre Hospitalier Universitaire Ambroise Pare - Boulogne

Boulogne, , France

Centre Hospitalier

Chalon-sur-Saône, , France

Hopital Antoine Beclere

Clamart, , France

Hopital Du Bocage

Dijon, , France

Clinique Pasteur

Guilherand-Granges, , France

CMC Les Ormeaux

Le Havre, , France

C. H. Du Mans

Le Mans, , France

Hopital Robert Boulin

Libourne, , France

Polyclinique des Quatre Pavillons

Lormont, , France

CHR D'Orleans - Hopital de la Source

Orléans, , France

Hopital Europeen Georges Pompidou

Paris, , France

Hopital Bichat - Claude Bernard

Paris, , France

CHU Pitie-Salpetriere

Paris, , France

Hopital Cochin

Paris, , France

Centre Hospitalier de Perpignan

Perpignan, , France

Hopital Sebastopol, C.H.U. de Reims

Reims, , France

Centre Eugene Marquis

Rennes, , France

Hopital Charles Nicolle

Rouen, , France

C.H. Senlis

Senlis, , France

CHRU de Tours - Hopital Trousseau

Tours, , France

Centre Hospitalier General - St. Nicolas

Verdun, , France

Countries

France

Other Identifiers

FFCD-0305

Identifier Type: -

Identifier Source: secondary_id

EU-20545

Identifier Type: -

Identifier Source: secondary_id

EUDRACT-2004-004742-40

Identifier Type: -

Identifier Source: secondary_id

CDR0000453857

Identifier Type: -

Identifier Source: org_study_id